Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer.

Citation metadata

From: Current Oncology Reports(Vol. 23, Issue 11)
Publisher: Springer
Document Type: Report; Brief article
Length: 242 words

Document controls

Main content

Abstract :

Keywords: Breast cancer; Novel HER2 agents; Cardiotoxicity; Cardiac monitoring Abstract Purpose of Review HER2-targeted therapies have led to improved clinical outcomes in early and advanced breast cancer (BC). We review the long-term cardiotoxicity of HER2-targeted therapy in early and advanced BC, our current knowledge of cardiotoxicity of novel HER2-targeted therapies, and propose a cardiac monitoring (CM) strategy for this population. Recent Findings Long-term data from studies with HER2-targeted therapy in the adjuvant setting have failed to demonstrate an increase in cardiotoxicity over time, and rates of cardiotoxicity seen with novel HER2 agents remain low. Despite over a decade of experience with HER2-targeted therapy, CM in clinical practice is inconsistent in patients with early BC and almost non-existent in advanced BC. Summary Long-term follow-up of clinical trials with HER2-targeted agents in early and advanced BC has failed to demonstrate increased rates of cardiotoxicity over time, attesting to the long-term safety of this class of drugs for the majority of patients, although the long-term cardiac safety of newer HER2 agents in the non-clinical trial setting is largely unknown. We propose CM incorporating clinical history, cardiac imaging, and biomarkers. Author Affiliation: (1) Duke Cancer Institute, Duke University, DUMC 3446, 27710, Durham, NC, USA (2) Harrington Heart and Vascular Institute, Case Western Reserve University, Cleveland, OH, USA (3) Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, OH, USA (a) susan.dent@duke.edu Article History: Registration Date: 07/28/2021 Accepted Date: 07/01/2021 Online Date: 08/27/2021 Byline:

Source Citation

Source Citation   

Gale Document Number: GALE|A673485772